Collapse of the MOF under tumor-specific conditions releases NLG919 to suppress IDO-mediated immune tolerance, while NIR-triggered plasmonic catalysis activates the chemotherapeutic component, inducing ICD and amplifying antitumor responses [93]. Here, IDO1 is linked to neoplasm.